Literature DB >> 31587784

MRI of Cardiotoxicity.

Jennifer Hawthorne Jordan1, William Gregory Hundley2.   

Abstract

Cardiovascular magnetic resonance (CMR) imaging is useful to identify systolic dysfunction, particularly when echocardiographic imaging is not acceptable because of poor acoustic windows or when left ventricular ejection fraction (LVEF) is inconclusive by other modalities and an accurate LVEF measurement is needed. Of particular advantage in cardio-oncology is CMR's capability to perform tissue characterization to noninvasively identify changes in pathologic conditions related to cancer therapy or to discriminate causes of disease that may confound presentation in cardio-oncology patients. For these reasons, there is an increasing use of CMR in the screening and surveillance of cardio-oncology patients.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiotoxicity; Cardiovascular magnetic resonance; Imaging; Left ventricular ejection fraction; Myocardial strain; Tissue characterization

Mesh:

Substances:

Year:  2019        PMID: 31587784      PMCID: PMC9200142          DOI: 10.1016/j.ccl.2019.07.007

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.410


  55 in total

Review 1.  Trastuzumab-induced cardiac dysfunction.

Authors:  Gurusher Singh Panjrath; Diwakar Jain
Journal:  Nucl Med Commun       Date:  2007-02       Impact factor: 1.690

2.  Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors.

Authors:  D De Wolf; B Suys; R Maurus; Y Benoit; H Verhaaren; D Matthijs; J Otten
Journal:  Pediatr Res       Date:  1996-03       Impact factor: 3.756

Review 3.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

4.  Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans.

Authors:  Andrew S Flett; Martin P Hayward; Michael T Ashworth; Michael S Hansen; Andrew M Taylor; Perry M Elliott; Christopher McGregor; James C Moon
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

5.  Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines.

Authors:  Tomas G Neilan; Otavio R Coelho-Filho; Diego Pena-Herrera; Ravi V Shah; Michael Jerosch-Herold; Sanjeev A Francis; Javid Moslehi; Raymond Y Kwong
Journal:  Am J Cardiol       Date:  2012-08-21       Impact factor: 2.778

6.  Early incidence of adriamycin treatment on cardiac parameters in the rat.

Authors:  Y Cottin; C Ribuot; V Maupoil; D Godin; L Arnould; F Brunotte; L Rochette
Journal:  Can J Physiol Pharmacol       Date:  1994-02       Impact factor: 2.273

7.  The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.

Authors:  Philip S Hall; Lauren C Harshman; Sandy Srinivas; Ronald M Witteles
Journal:  JACC Heart Fail       Date:  2013-02-04       Impact factor: 12.035

8.  Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.

Authors:  Brandon C Drafts; Katie M Twomley; Ralph D'Agostino; Julia Lawrence; Nancy Avis; Leslie R Ellis; Vinay Thohan; Jennifer Jordan; Susan A Melin; Frank M Torti; William C Little; Craig A Hamilton; W Gregory Hundley
Journal:  JACC Cardiovasc Imaging       Date:  2013-05-01

9.  Left Ventricular Mass Change After Anthracycline Chemotherapy.

Authors:  Jennifer H Jordan; Sharon M Castellino; Giselle C Meléndez; Heidi D Klepin; Leslie R Ellis; Zanetta Lamar; Sujethra Vasu; Dalane W Kitzman; William O Ntim; Peter H Brubaker; Nathaniel Reichek; Ralph B D'Agostino; W Gregory Hundley
Journal:  Circ Heart Fail       Date:  2018-07       Impact factor: 8.790

10.  Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy.

Authors:  Marie-Pierre Jolly; Jennifer H Jordan; Giselle C Meléndez; Gary R McNeal; Ralph B D'Agostino; W Gregory Hundley
Journal:  J Cardiovasc Magn Reson       Date:  2017-08-02       Impact factor: 5.364

View more
  2 in total

1.  Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors.

Authors:  Nikki van der Velde; Cécile P M Janus; Daniel J Bowen; H Carlijne Hassing; Isabella Kardys; Flora E van Leeuwen; Cynthia So-Osman; Remi A Nout; Olivier C Manintveld; Alexander Hirsch
Journal:  JACC CardioOncol       Date:  2021-12-21

Review 2.  Emerging Challenges of Radiation-Associated Cardiovascular Dysfunction (RACVD) in Modern Radiation Oncology: Clinical Practice, Bench Investigation, and Multidisciplinary Care.

Authors:  Moon-Sing Lee; Dai-Wei Liu; Shih-Kai Hung; Chih-Chia Yu; Chen-Lin Chi; Wen-Yen Chiou; Liang-Cheng Chen; Ru-Inn Lin; Li-Wen Huang; Chia-Hui Chew; Feng-Chun Hsu; Michael W Y Chan; Hon-Yi Lin
Journal:  Front Cardiovasc Med       Date:  2020-02-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.